CTXR

Stats

Summary

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.

Market Cap: 114 Million

Primary Exchange: NASDAQ

Website: https://www.citiuspharma.com/

Shares Outstanding: 159 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.3159733032853398

Sector: Manufacturing

Industry: Medicinal and Botanical Manufacturing

Ethical Flags

Longest drawdown: 2704 trading days

From: 2016-02-09 To: 2024-03-07

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor
2017-06-09				15.0	1.0	15.0